Meet the ophthalmology-focused pharmaceutical company trying to raise $86M

Tarsus Pharmaceuticals is attempting to raise $86 million through an initial public offering, Nasdaq reports.

Tarsus is a late-stage biopharmaceutical company focused on developing therapies for ophthalmology conditions.

Tarsus' lead pipeline candidate, TP-03, is attempting to treat Demodex blepharitis. This treatment has completed four phase 2 trials to date. It expects to launch a phase 2b/3 trial in September.

Tarsus was founded in 2016.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast